Making a case “for” focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients wi...

Full description

Saved in:
Bibliographic Details
Published in:World journal of urology 2021-03, Vol.39 (3), p.729-739
Main Authors: Wang, Alex Z., Lebastchi, Amir H., O’Connor, Luke P., Ahdoot, Michael, Mehralivand, Sherif, Yerram, Nitin, Taneja, Samir S., George, Arvin K., Sanchez-Salas, Rafael, Ward, John F., Laguna, Pilar, de la Rosette, Jean, Pinto, Peter A.
Format: Article
Language:English
Subjects:
Clinical trials
Medicine
Medicine & Public Health
Nephrology
Oncology
Prostate cancer
Topic Paper
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical “middle ground” in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.
ISSN:0724-4983
1433-8726
DOI:10.1007/s00345-020-03525-0